Market Access News | pharmaphorum

News

EU approves Roche's Actemra for severe COVID-19

The European Commission has moved swiftly to grant full approval to Roche's Actemra/RoActemra as a treatment for severe COVID-19, clearing the drug within 24 hours of a recommendation from

Market Access

scientifically visualization of a coronavirus spike protein

MHRA okays GSK's Xevudy as data suggest it works against Omi...

The UK medicines regulator has approved GlaxoSmithKline and Vir Biotech's antibody for COVID-19, Xevudy, which has been shown to be effective against the new Omicron strain of SARS-CoV-2 in

News

Merck's oral COVID drug squeaks past FDA advisory committee

An FDA advisory committee voted by 13 to 10 to recommend emergency-use authorisation for Merck & Co and Ridgeback's oral antiviral molnupiravir for mild-to-moderate COVID-19, saying it

News

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start

News

Turkey's home-grown COVID vaccine project nears fruition

Turkey could have its own COVID-19 vaccine Turkovac available for use by the end of the year, according to the country's Health Minister Fahrettin Koca.

News

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

Eli Lilly's RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England and Wales, within the Cancer D

EU approves Roche's Actemra for severe COVID-19

MHRA okays GSK's Xevudy as data suggest it works against Omi...

Merck's oral COVID drug squeaks past FDA advisory committee

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

Turkey's home-grown COVID vaccine project nears fruition

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks